These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18536113)

  • 21. Lp A-I and niacin: new views of an antiatherogenic duo.
    Saucan L; Brinton EA
    Arterioscler Thromb Vasc Biol; 2001 Nov; 21(11):1707-9. PubMed ID: 11701453
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
    Masson D
    Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. On the road to better dyslipidemia outcomes.
    Hughes S
    Nurse Pract; 2009 Feb; 34(2):14-21; quiz 22. PubMed ID: 19155874
    [No Abstract]   [Full Text] [Related]  

  • 25. Lipid management in the geriatric patient.
    Nair AP; Darrow B
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):185-206. PubMed ID: 19217519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of lipid-lowering drug therapy in children and adolescents.
    Avis HJ; Vissers MN; Wijburg FA; Kastelein JJ; Hutten BA
    Curr Opin Investig Drugs; 2009 Mar; 10(3):224-31. PubMed ID: 19333879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).
    Alrasadi K; Awan Z; Alwaili K; Ruel I; Hafiane A; Krimbou L; Genest J
    Am J Cardiol; 2008 Nov; 102(10):1341-7. PubMed ID: 18993152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development.
    Zhao L; Jin W; Rader D; Packard C; Feuerstein G
    Biochem Pharmacol; 2009 Aug; 78(4):315-25. PubMed ID: 19539799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Where now for new drugs for atherosclerosis?
    Opar A
    Nat Rev Drug Discov; 2007 May; 6(5):334-5. PubMed ID: 17539053
    [No Abstract]   [Full Text] [Related]  

  • 30. [Treatment of dyslipoproteinemia risk factor. Lipid therapy must become multidimensional].
    MMW Fortschr Med; 2008 Jun; 150(26-27):52-3. PubMed ID: 18681233
    [No Abstract]   [Full Text] [Related]  

  • 31. Treating hypertriglyceridemia.
    Röggla G; Fasan M; Kapiotis S
    CMAJ; 2007 Sep; 177(6):603; author reply 604-5. PubMed ID: 17846444
    [No Abstract]   [Full Text] [Related]  

  • 32. [Pleiotropic effects of fibric acid derivatives (Lipanthyl-200) among patients with metabolic syndrome].
    Zvenigorodskaia LA; Mel'nikova NV; Bondarenko EIu
    Eksp Klin Gastroenterol; 2007; (1):41-6. PubMed ID: 17547112
    [No Abstract]   [Full Text] [Related]  

  • 33. Is high HDL cholesterol always good?
    Olsson AG
    Ann Med; 2009; 41(1):11-8. PubMed ID: 19085339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P
    Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cholesteryl ester transfer protein inhibition for coronary heart disease prevention: real hope or despair?
    Frishman WH; Barkowski RS
    Am J Med; 2008 Aug; 121(8):644-6. PubMed ID: 18691473
    [No Abstract]   [Full Text] [Related]  

  • 36. Pyrazole acids as niacin receptor agonists for the treatment of dyslipidemia.
    Schmidt D; Smenton A; Raghavan S; Carballo-Jane E; Lubell S; Ciecko T; Holt TG; Wolff M; Taggart A; Wilsie L; Krsmanovic M; Ren N; Blom D; Cheng K; McCann PE; Gerard Waters M; Tata J; Colletti S
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4768-72. PubMed ID: 19592242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-density lipoprotein and atheroma monitoring.
    Nicholls SJ; Tuzcu EM
    Curr Opin Cardiol; 2008 Jul; 23(4):386-92. PubMed ID: 18520724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treating hypertriglyceridemia.
    Yavasoglu I; Kadikoylu G; Bolaman Z
    CMAJ; 2007 Sep; 177(6):603-4; author reply 604-5. PubMed ID: 17846443
    [No Abstract]   [Full Text] [Related]  

  • 39. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
    Shinkai H
    Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cardiovascular system drugs. 9/12. Antilipemics--II. Fibrates and colestyramine].
    Nerich V; Limat S
    Soins; 2005; (692):57-8. PubMed ID: 15787412
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.